Moreover, the newly released findings of the I-SPY2 clinical trial, which assessed the efficacy of anti-LAG-3 and anti-PD1 treatment in patients with early-stage HER2-negative breast cancer, indicated a projected pathologic complete response rate of 60% for individuals with hormone receptor HR-negative, HER2-negative disease and 37% for those with HR-positive, HER2-negative disease (114). This evidence concerns the gene LAG3 and breast cancer.